#Germany #Düsseldorf #Monoclonal Antibodies #LenioBio #mAIbe

mAIbe and LenioBio: A New Era in Monoclonal Antibody Discovery

In an exciting development for the biotechnology landscape, mAIbe, renowned for its AI-guided monoclonal antibody design, has partnered with LenioBio, a leading company in cell-free protein expression. This strategic collaboration, announced on November 26, 2025, is set to revolutionize the discovery and experimental validation processes for next-generation monoclonal antibodies.

This partnership aims to bring together two complementary strengths: mAIbe’s innovative AI-driven platform for antibody design and optimization, and LenioBio’s cutting-edge cell-free expression technology. By integrating these approaches, the collaboration seeks to significantly enhance the ‘design–build–test’ cycle that is crucial for developing effective therapeutic antibodies.

Accelerating Antibody Production

LenioBio’s ultrafast and scalable expression system allows for the rapid production of complex antibodies. This capability is critical because it enables the generation of high-quality experimental data that feeds directly into mAIbe's AI models. As a result, both companies anticipates that this partnership will not only expedite functional testing of AI-generated antibody candidates but also improve efficiency and throughput during the early validation stages.

Moreover, one of the key advantages of this collaboration is the potential for faster iterations between computational predictions and experimental outcomes. This means that findings from laboratory tests can quickly inform further computational work, creating a feedback loop that accelerates the entire antibody development process.

Setting a New Standard

The synergy created between mAIbe’s sophisticated technology and LenioBio’s innovative expression methods is expected to set a new benchmark for speed, flexibility, and data-driven insights in the realm of therapeutic antibody discovery. This collaborative effort addresses a critical gap known as the lab-in-loop challenge, which has historically hindered the quick translation of research into practical applications in the health sector.

Insights into the Companies

LenioBio was founded in 2016 and is based in Düsseldorf, Germany. It specializes in cell-free protein expression, which allows for the rapid discovery and scalable production of proteins unbound by the limitations of traditional cell-based systems. With its ALiCE® platform, the company is pushing the boundaries of protein development, making it a pivotal player in biotechnology.

On the other hand, mAIbe, headquartered in Rome, Italy, focuses on the integration of physics-informed generative AI and synthetic biology. Its innovative platform is tailored specifically for the design of monoclonal antibodies that target viral and bacterial pathogens. By leveraging artificial intelligence within life sciences, mAIbe aims to accelerate the development of accessible, next-generation immunotherapies.

Looking Ahead

With the biomedical landscape continuously evolving, the collaboration between mAIbe and LenioBio represents a significant step forward. Both companies are poised to lead innovation in monoclonal antibody research, thereby addressing critical health challenges through their groundbreaking technologies. As this partnership unfolds, it could potentially change the way therapeutic antibodies are developed, tested, and brought to market, making a real difference in patient care outcomes.

For more information on LenioBio and mAIbe, visit their respective websites: LenioBio and mAIbe. Together, they are set to redefine the future of antibody production and therapeutic development.